GlassScriptPhysician profile
Ruba Nijmeh
NPI 1396959755
$1,854.31
in general payments reported to CMS, 2019-2025
26 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $81.48 · 2021: $47.64 · 2022: $170 · 2023: $202 · 2024: $433 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958 · Education: $33.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.74 |
| Education | $33.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $226.06 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $172.85 | 2019-2025 | Velphoro |
| Novo Nordisk INC | $171.75 | 2023-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $160.55 | 2021-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $142.01 | 2019-2024 | Jynarque |
| Glaxosmithkline, LLC. | $121.05 | 2022-2023 | Benlysta |
| Janssen Pharmaceuticals, INC | $119.53 | 2019 | |
| Calliditas Therapeutics US INC. | $113.96 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.45 | 2022-2024 | |
| Amgen INC. | $56.95 | 2019-2025 | Tavneos |
| Genzyme Corporation | $49.58 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $48.71 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $41.15 | 2019-2020 | |
| Lundbeck LLC | $37.55 | 2019-2020 | |
| Vifor Pharma, INC. | $35.56 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $34.37 | 2019 | |
| Travere Therapeutics, INC. | $33.58 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $33.20 | 2025 | |
| Horizon Therapeutics Plc | $27.87 | 2019 | |
| Baxter Healthcare | $23.09 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.34 | 2023 | Jardiance |
| Ardelyx, INC. | $20.00 | 2023 | Ibsrela |
| Opko Pharmaceuticals, LLC | $17.69 | 2019 | |
| Daiichi Sankyo INC. | $17.51 | 2019 | |
| Outset Medical INC | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruba Nijmeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.